Brooks Laboratories Limited focuses on critical care products including Beta Lactam, Cephalosporin, and General Dry powder Injectables. It provides a diverse product portfolio for multiple companies.

Brooks Laboratories major competitors are Zim Laboratories, Albert David, Lyka Labs, Medicamen Biotech, Trident Lifeline, Jenburkt Pharma, Medico Remedies.
Market Cap of Brooks Laboratories is ₹409 Crs.
While the median market cap of its peers are ₹364 Crs.

Brooks Laboratories seems to be financially stable compared to its competitors.
The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.